Radiomics.bio

Liège, Belgium All Belgium companies → — Founded 2016

Biotech / Drug Discovery Imaging AI Specialist Specialty-Focused AI

Venture Capital-Backed (Series B)

Claim this company

Products

Radiomics App

Radiomics.bio

Developer Tools & APIs

Microsoft's Project InnerEye is an open-source deep learning toolkit for quantitative analysis of 3D medical images, enabling radiomics research and accelerating tasks like radiotherapy planning. It serves as a foundation for broader Microsoft healthcare AI initiatives.

See all 1 product →

About Radiomics.bio

Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization (CRO) that specializes in optimizing the development of new oncology treatments. The company leverages radiomics, deep learning, and federated learning to extract quantitative biomarker measurements from medical images such as CT, PET, and MRI. This process aims to uncover hidden information within standard medical images that is not visible to the naked eye, providing more comprehensive and quantitative insights than traditional imaging analysis methods like RECIST.

For physicians, Radiomics.bio’s technology can aid in various aspects of oncology, including diagnosis (detecting and classifying tumors), histology prediction (predicting tumor subtypes and staging), genetic expression analysis (detecting underlying biomarkers), response prediction (classifying responders vs. non-responders to therapy), immune-related expression analysis, and prognosis (predicting overall survival). In clinical trials, their services can help characterize disease, quantify drug impact, evaluate treatment response, identify imaging biomarkers, and predict outcomes, thereby facilitating objective, insight-based decision-making throughout all phases of clinical development.

Focus Areas

AI-powered medical imaging advanced statistics oncology deep learning federated learning clinical trials drug development precision medicine imaging biomarkers

Business Intelligence

Technology

Ikonics® platform (cloud-native, AI-powered image management and analysis platform)

What Physicians Need to Know

AI-Powered Medical Imaging

Radiomics.bio specializes in extracting quantitative biomarker measurements from medical images (CT, PET, MRI) using AI and advanced statistics. This reveals hidden information and provides quantitative insights beyond standard visual analysis, aiding in disease characterization, treatment response evaluation, and outcome prediction.

Oncology Focus

The company is a pioneer in applying radiomics to oncology, optimizing the development of new cancer treatments. They offer services for diagnosis, histology prediction, genetic expression analysis, response prediction, immune-related expression, and prognosis in cancer patients.

Clinical Trials & Drug Development

Radiomics.bio supports pharmaceutical and biotech companies throughout all stages of clinical development. They use their Ikonics® platform and expertise to optimize clinical trial designs, quantify treatment response, explore drug mechanisms of action, identify imaging biomarkers, and predict patient outcomes, aiming to reduce clinical trial failure rates.

Federated Learning for Data Privacy

They utilize federated learning, particularly with their DistriM solution, to train AI models on decentralized data while maintaining patient data privacy and security within each clinical center. This approach addresses data silos and minimizes legal and administrative hurdles.

Precision Medicine & Imaging Biomarkers

Radiomics.bio's work contributes to precision medicine by identifying imaging biomarkers that can predict disease progression, treatment response, and clinical outcomes. This allows for personalized treatment strategies and optimized patient selection.

Physician Tip

For physicians, Radiomics.bio offers tools and insights that can enhance diagnostic accuracy, personalize treatment plans, and predict patient responses to therapies. Their AI-powered analysis of medical images can reveal subtle patterns and quantitative data not visible to the naked eye, leading to earlier detection of disease, more informed treatment decisions, and improved patient outcomes. The use of radiomics can help in characterizing disease at lesion, organ, and patient levels, evaluating treatment efficacy beyond traditional methods like RECIST, and identifying patients most likely to respond to specific treatments. Their federated learning approach ensures patient data privacy while still leveraging large datasets for robust AI model development.

Radiomics.bio's Ikonics® platform is a fully integrated image management system that streamlines image collection, centralizes quality assessment, and facilitates the radiomic pipeline from data acquisition to AI modeling and statistical analysis. They also offer central imaging services for clinical trials, including image collection, curation, control, and storage, adhering to regulatory and privacy requirements. The platform supports various imaging modalities such as CT, PET, and MRI.

Products by Radiomics.bio

1 product in the directory

Radiomics App

Radiomics.bio

Developer Tools & APIs

What the Web Says

Radiomics.bio is an AI-powered medical imaging and advanced statistics clinical research organization that focuses on optimizing the development of new oncology treatments. They offer services like disease characterization, response evaluation, and outcome prediction using radiomics and AI to provide insights for clinical trials and drug development. The company aims to improve patient selection, treatment efficacy, and reduce costs in clinical trials.

Overall: Mixed

Strengths

Pioneer in the field of radiomics.
Offers AI-powered medical imaging and advanced statistics.
Optimizes clinical trials and drug development in oncology.
Provides insights for decision-making in early stages of treatment.
Helps predict patient response to treatment.
Multidisciplinary and multicultural team with experienced scientists and technology experts.

Limitations

No specific product or employer reviews found on G2, Glassdoor, or Capterra.
General challenges in radiomics include data acquisition, repeatability, and reproducibility of features.
Radiomics studies are often constrained by small sample sizes from single institutions.
Integration of AI in clinical practice faces obstacles like heavy hierarchy and entrenched legacy software.
Radiomics has mostly seen success in oncology settings where only the tumor volume is segmented, making applications to whole organs more speculative.
A large portion of radiomics features may not have predictive value without feature reduction.

Based on reviews from: reddit.com, radiomics.bio, collectiveminds.health, researchgate.net, mdpi.com, revenuebase.ai, g2.com, capterra.com, wikipedia.org

Last updated: 2026-10-31

Videos

News, demos, and interviews about Radiomics.bio.

Loading videos...

Videos load interactively. If none appear, search YouTube for Radiomics.bio →

View all on YouTube

Press & Coverage

radiomics.bio

radiomics.bio and AstraZeneca join forces to explore the potential for an AI model to predict interstitial lung disease related to cancer treatment

Radiomics.bio and AstraZeneca are collaborating to develop an AI model to predict interstitial lung disease (ILD) related to cancer treatment, a potentially fatal adverse event. This partnership aims to leverage AI to improve patient management and reduce healthcare costs by identifying high-risk patients earlier.

2025-10

radiomics.bio

radiomics.bio Announces New Chairman

Radiomics.bio announced the appointment of Dr. Jan Groen as the new chairman of its board of directors, succeeding Dr. Michel Baijot. Dr. Groen brings over 25 years of experience in clinical precision diagnostics and the biotech industry, aiming to expand the company's commercial pharma service rollout.

2025-03

radiomics.bio

From Images to Impact: Radiomics' Solutions to Challenges in Immunotherapy

Radiomics.bio conducted a retrospective study demonstrating the ability of CT-based radiomics and delta-radiomics to predict tumoral response and survival in NSCLC patients treated with PD-1/PD-L1 inhibitors. This research highlights the potential of AI and radiomics to revolutionize immunotherapy response assessment.

2024-02

radiomics.bio

Pilot project at the Jewish General Hospital aims to accelerate access to new and highly effective treatments for cancer patients

A collaborative research project, 'Digital Health to Advance and Support Precision Oncology,' supported by a grant from the Ministry of Economy, Innovation and Energy (MEIE) and TransMedTech Institute, aims to accelerate access to new cancer treatments. Radiomics.bio is a partner in this initiative, focusing on AI-powered healthcare.

2023-09

radiomics.bio

DeuterOncology joins forces with Radiomics to develop a clinical tool to predict patient response to treatment

DeuterOncology received a 478,000 EUR Win4Company grant to partner with Radiomics.bio for the development and validation of an AI-based imaging biomarker. This collaboration aims to predict patient response to treatment for lung cancer patients with MET gene alterations.

2023-04

springermedizin.de

Radiomics: the bridge between medical imaging and personalized medicine

This article discusses radiomics as an innovative field extracting quantitative imaging features from medical images to provide more information for personalized medicine. It highlights the potential of radiomics to identify image-based biomarkers for diagnostic, prognostic, or predictive purposes.

2023-04

radiomics.bio

Three Lakes Foundation Announces Expansion of B4PF Initiative to Accelerate Early Diagnosis and Therapeutic Development for Pulmonary Fibrosis

Three Lakes Foundation expanded its B4PF initiative, collaborating with Weill Cornell Medicine, Vanderbilt University Medical Center, and Radiomics.bio, to improve early diagnosis and therapeutic development for pulmonary fibrosis. Radiomics.bio will contribute its imaging research expertise to this effort.

2022-11

radiomics.bio

Radiomics is pleased to announce its Quality Management System has been certified to be fully compliant with EN ISO 13485:2016 Medical Devices – Quality Management Systems – Requirements for regulatory purposes) standard by the notified body IMQ.

Radiomics.bio announced that its Quality Management System has achieved EN ISO 13485:2016 certification, demonstrating compliance with regulatory requirements for medical devices. This certification covers the design and development of Software as a Medical Device for diagnosis, prognosis, or prediction of disease progression using clinical imaging.

2022-03

Frequently Asked Questions

What specific AI-powered medical imaging products or services does Radiomics.bio offer for oncology?

Radiomics.bio offers AI-powered medical imaging and advanced statistics as a clinical research organization focused on optimizing oncology treatments. Their services include disease characterization, response evaluation, response characterization, and outcome prediction, all leveraging radiomics to extract quantitative insights from medical images. They also provide central imaging services and utilize their Ikonics® platform for efficient image management and analysis.

How does Radiomics.bio ensure compliance and data privacy, especially with advanced techniques like federated learning?

Radiomics.bio prioritizes safety and trust, adhering to ISO 13485 and ISO 27001 standards, and following MDR and FDA guidelines for medical devices and services. They ensure pseudo-anonymization of data by removing personal identifiable information before ingestion. For federated learning, Radiomics.bio's DistriM solution keeps data secure within each clinical center, standardizing and anonymizing it without it ever leaving its source, thereby enhancing accuracy without compromising privacy.

What is the typical pricing model for Radiomics.bio's services, and how does it vary based on the scope of a clinical trial or drug development project?

While specific pricing models are not publicly detailed, Radiomics.bio emphasizes cost efficiency through its quality assurance processes, aiming to offer high-quality services and devices at competitive prices. Their services are designed to provide insightful and cost-effective clinical trial designs by enhancing understanding of disease and treatment response.

What kind of support does Radiomics.bio provide to physicians and healthcare administrators during the integration and use of their imaging biomarkers and AI models?

Radiomics.bio positions itself as an expert partner for the pharmaceutical industry, offering support from image acquisition to regulatory reporting. They provide comprehensive image-based insights for clinical trials and offer expertise in adjusting, detailing, or fully developing optimal imaging protocols for clinical studies. They also offer customer support for inquiries, order processing, service delivery, and maintaining client relationships.

Can you describe Radiomics.bio's key partnerships and how these collaborations enhance their offerings in precision medicine and oncology?

Radiomics.bio has established partnerships with biotech and pharma companies, scientific partners, investors, and financial and institutional partners. Notable collaborations include joining forces with AstraZeneca to explore AI models for predicting interstitial lung disease related to cancer treatment and partnering with DeuterOncology to develop AI-based imaging biomarkers for personalized cancer therapy, specifically for identifying lung cancer patients with MET gene alterations. These partnerships aim to optimize decision-making in drug development and improve patient outcomes.

What is the company's stability and track record? How long has Radiomics.bio been in operation, and what is its funding status?

Radiomics.bio was founded in 2016 in Liège, Belgium. The company has raised $11.8 million in funding over three rounds. They are described as a funded company with a focus on optimizing oncology treatments through AI-powered medical imaging and advanced statistics.

How does Radiomics.bio address the concerns regarding the reproducibility and validation of imaging biomarkers in clinical trials?

Radiomics.bio emphasizes rigorous scientific evidence and clinical validation for its services and devices. Their Ikonics® platform ensures full traceability and auditability of imaging processing steps, including data collection, image quality assessment, 3D segmentation, and labeling. They also provide central imaging lab services with ISO 27001 validated Quality Management Systems to ensure high-quality treatment efficacy assessment.

Related Companies

Suggest an Edit → | Report an issue